U.S. market Closed. Opens in 4 hours

NTLA | Intellia Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Revenue36.27M52.12M33.05M57.99M43.10M30.43M26.12M16.48M6.04M
Cost of Revenue8.98M7.57M6.89M150.41M108.41MN/AN/AN/AN/A
Gross Profit27.30M44.55M26.16M-92.41M-65.31M30.43MN/AN/AN/A
Operating Expenses551.57M510.29M300.90M194.58M149.47M121.30M95.67M48.64MN/A
Selling, General & Admin116.50M90.31M71.10M44.17M41.06M32.19M28.02M16.80M8.28M
Research & Development435.07M419.98M229.81M150.41M108.41M89.11M67.65M31.84M11.17M
Other Operating Expenses-435.07MN/AN/AN/AN/AN/AN/AN/AN/A
Operating Income-515.29M-458.16M-267.85M-136.58M-106.37M-90.87M-69.56M-32.16M-13.41M
Other Expenses / Income-15.73M-16.02M-42.00K2.35M6.83M5.53M2.01M525.00KN/A
Before Tax Income-481.19M-474.19M-267.89M-134.23M-99.53M-85.34M-67.54M-31.63M-13.41M
Income Tax Expenses-49.73M16.02M-8.17M-8.66M-6.83M5.53MN/AN/A-1.01M
Net Income-481.19M-490.21M-259.72M-125.57M-92.70M-85.34M-67.54M-31.63M-12.40M
Interest ExpensesN/A8.54MN/AN/AN/AN/AN/AN/AN/A
Basic Shares Outstanding88.77M76.97M70.89M55.99M47.25M43.07M36.01M22.22M17.66M
Diluted Shares Outstanding88.77M76.97M70.89M55.99M47.25M43.07M36.01M22.22M17.66M
EBITDA-506.21M-444.68M-267.85M-136.58M-100.78M-90.87M-64.55M-30.53M-13.08M
EBITDA Margin-1,395.49%-853.17%-810.37%-235.51%-233.81%-298.58%-247.15%-185.27%-216.43%
EBIT-530.92M-465.64M-267.89M-134.23M-99.53M-79.82M-67.54M-31.63M-13.41M
EBIT Margin-1,463.61%-893.39%-810.49%-231.46%-230.92%-262.26%-258.62%-191.97%-221.86%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙